Scientific Program of 32nd World Congress of Endourology & SWL Program Book

Abstract

INTRODUCTION AND OBJECTIVES: Ureteal stents after Ureteroscopic surgery are often necessary to provide adequate urine passage and for other purposes. Unfortunately, pain and lower urinary tract symptoms are often associated with stents. Our goal is to determine whether solifenacin can relieve such symptoms. METHODS: A total of 70 patients scheduled for unilateral retrograde ureteroscopy with stent placement. Patients were randomized between placebo and solifenacin 5mg medication group, and investigators and patients were blinded to the randomization scheme. To evaluate pain and lower urinary symptoms, patients were asked to complete Visual analogue scale for pain, OABSS, IPSS and voiding diary on 7 days and 14 days after the procedure. To minimize the impact of LUTS caused by ureter stone, Patients were asked to completed OABSS and IPSS by their memory of 1 month ago for baseline status. RESULTS: Of 70 patients who provided consent, 69 successfully completed the study. One patient was excluded from study after obtaining consent due to severe dry mouth. There were no significant differences between the placebo and vesicare arms regarding stent type, procedure complications and baseline questionnaire results. When comparing post-procedure questionnaire results, patients in the solifenacin arm reported less overall pain (2.0735 vs 3.6447, p = 0.0017 in 1 week, 2.3143 vs 3.2237 p = 0.0488 in 2 weeks). There was no significant difference in change of OABSS, number of micturition, IPSS score, narcotics use, as reported in patient medication logs. CONCLUSIONS: Although Solifenacin did not improve objective parameters for LUTS, it improved the patient's subjective pain associated with ureteral stents.